Elite in Rhabdomyosarcoma

Dr. Leonard Wexler

Hematology | Oncology
Memorial Sloan Kettering Bergen
225 Summit Ave, 
Montvale, NJ 
Accepting New Patients
Elite in Rhabdomyosarcoma
Memorial Sloan Kettering Bergen
225 Summit Ave, 
Montvale, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Leonard Wexler is a Hematologist and an Oncologist in Montvale, New Jersey. Dr. Wexler is rated as an Elite provider by MediFind in the treatment of Rhabdomyosarcoma. His top areas of expertise are Rhabdomyosarcoma, Adult Soft Tissue Sarcoma, Ewing Sarcoma, Hepato-Pancreato-Biliary Surgery, and Orchiectomy. Dr. Wexler is currently accepting new patients.

His clinical research consists of co-authoring 93 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 47 articles and participated in 2 clinical trials in the study of Rhabdomyosarcoma.

Specialties
Hematology
Oncology
Licenses
Pediatric Hematology-Oncology in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 3 Less Insurance Carriers -

Locations

Memorial Sloan Kettering Bergen
225 Summit Ave, Montvale, NJ 07645

Additional Areas of Focus

Dr. Wexler has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients With High Risk Rhabdomyosarcoma (HR-RMS)
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients With High Risk Rhabdomyosarcoma (HR-RMS)
Enrollment Status: Active_not_recruiting
Publish Date: December 22, 2025
Intervention Type: Procedure, Drug, Biological, Radiation
Study Drug: Cyclophosphamide
Study Phase: Phase 3
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Combination With Irinotecan and Temozolomide as a Second-Line Regimen for Ewing's Sarcoma
A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Combination With Irinotecan and Temozolomide as a Second-Line Regimen for Ewing's Sarcoma
Enrollment Status: Terminated
Publish Date: April 26, 2023
Intervention Type: Drug, Biological
Study Drugs: Vigil, Irinotecan, Temozolomide
Study Phase: Phase 3
A 2-part Trial Comparing Overall Survival of Patients With Metastatic Ewing's Sarcoma Treated With Vigil Versus Gemcitabine and Docetaxel and to Determine Safety Profile of Vigil in Combination With Irinotecan and Temozolomide.
A 2-part Trial Comparing Overall Survival of Patients With Metastatic Ewing's Sarcoma Treated With Vigil Versus Gemcitabine and Docetaxel and to Determine Safety Profile of Vigil in Combination With Irinotecan and Temozolomide.
Enrollment Status: Completed
Publish Date: December 22, 2022
Intervention Type: Drug, Biological
Study Phase: Phase 2
View 3 Less Clinical Trials

92 Total Publications

Spectrum and Clinical Impact of Secondary Genetic Alterations in Translocation-Associated Sarcomas.
Spectrum and Clinical Impact of Secondary Genetic Alterations in Translocation-Associated Sarcomas.
Journal: JCO precision oncology
Published: October 30, 2025
Similar Doctors
Distinguished in Rhabdomyosarcoma
Dr. William D. Tap
Hematology Oncology | Hematology | Oncology
Distinguished in Rhabdomyosarcoma
Dr. William D. Tap
Hematology Oncology | Hematology | Oncology

Memorial Solid Tumor Group

160 E 53rd St, 
New York, NY 
 (0.8 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

William Tap is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Tap is rated as an Elite provider by MediFind in the treatment of Rhabdomyosarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Angiosarcoma, Tissue Biopsy, and Liver Embolization.

Distinguished in Rhabdomyosarcoma
Dr. Mary L. Keohan
Oncology | Hematology
Distinguished in Rhabdomyosarcoma
Dr. Mary L. Keohan
Oncology | Hematology

Memorial Solid Tumor Group

160 E 53rd St, 
New York, NY 
 (0.8 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mary Keohan is an Oncologist and a Hematologist in New York, New York. Dr. Keohan is rated as an Elite provider by MediFind in the treatment of Rhabdomyosarcoma. Her top areas of expertise are Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Liposarcoma, Liver Embolization, and Bone Marrow Aspiration.

Distinguished in Rhabdomyosarcoma
Dr. Sujana Movva
Oncology | Hematology Oncology | Hematology
Distinguished in Rhabdomyosarcoma
Dr. Sujana Movva
Oncology | Hematology Oncology | Hematology

Memorial Solid Tumor Group

1275 York Ave, 
New York, NY 
 (0.1 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sujana Movva is an Oncologist and a Hematologist Oncology provider in New York, New York. Dr. Movva is rated as an Elite provider by MediFind in the treatment of Rhabdomyosarcoma. Her top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Gastrointestinal Stromal Tumor, Pancreaticoduodenectomy, and Splenectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wexler's expertise for a condition
ConditionClose
View All 10 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile